The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.

The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the timeline for stakeholders to submit comments ...

Good intentions alone are not enough in 340B. Let’s get informed. The good news is that the growing national scrutiny of how the 340B program operates should be seen not as a threat, but as an ...

Hospitals and clinics in Michigan participating in a federal drug discount program are marking up medications and shifting costs onto public employee health plans, according to ...

A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

The federal government will pay eligible hospitals in the 340B program $9 billion to offset payment cuts the Supreme Court ruled unlawful last year. In 2018, the Department of Health and Human ...

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report. The 340B Drug Pricing Program has been under constant attack on ...

Some hospitals are buying life-saving medications for pennies, then charging low-income patients, including many with disabilities, hundreds of dollars for these drugs. They do it every day under a ...

Nonprofit hospitals aren’t abusing the 340B pricing program. The fault lies with profit-taking drugmakers.

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...